Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/19/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
- Delta Air Lines (DAL) Raises Quarterly Dividend 14.7% to $0.2150; 1% Yield
- Oil rises 1% on US-Iran deal doubts; IEA warns of supply glut
Fulcrum Therapeutics Inc. (FULC) Misses Q1 EPS by 1c
May 9, 2022 7:07 AM EDTFulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q1 EPS of ($0.64), $0.01 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $2.59 million versus the consensus estimate of $3.94 million.
For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.
... More